Chemical Component Summary

Name Clopidogrel
Identifiers methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)ethanoate
Formula C16 H16 Cl N O2 S
Molecular Weight 321.82 g/mol
Type non-polymer
Isomeric SMILES COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl
InChI InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChI Key GKTWGGQPFAXNFI-HNNXBMFYSA-N

Chemical Details

Formal Charge 0
Atom Count 37
Chiral Atom Count 1
Chiral Atoms CA
Bond Count 39
Aromatic Bond Count 11

Drug Info: DrugBank

DrugBank ID DB00758   (Stereoisomeric match)
Name Clopidogrel
Groups
  • approved
  • nutraceutical
Description Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
Synonyms
  • (+)-Clopidogrel
  • Clopidogrelum
Salts Clopidogrel Bisulfate
Brand Names
  • Abbott-clopidogrel
  • Accel-clopidogrel
  • Act Clopidogrel
  • Ag-clopidogrel
  • Apo-clopidogrel
Affected Organism Humans and other mammals
Indication For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
Pharmacology Since clopidogrel is a prodrug, it must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. This active metabolite selectively inhibits adenosine diphosphate (ADP) binding to its platelet P2Y12 receptor and subsequently the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Mechanism of action The active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. he drug specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel.
Route of administration oral
Categories Platelet Aggregation Inhibitors
ATC-Code B01AC04
AHFS-Code 20:12.18
CAS number 113665-84-2

Drug Targets

Name Sequence Search Pharmacological Action Actions
P2Y purinoceptor 12 Search yes antagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682